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Available online 11 February 2016Cardiac progenitor cells (CPCs) are a crucial source of cells in cardiac development and regeneration. However,
reported CPCs are heterogeneous, and no gene has been identiﬁed to transiently mark undifferentiated CPCs
throughout heart development. Here we show that Spalt-like gene 1 (Sall1), a zing-ﬁnger transcription factor, is
expressed in undifferentiated CPCs giving rise to both left and right ventricles. Sall1 was transiently expressed
in precardiac mesoderm contributing to the ﬁrst heart ﬁeld (left ventricle precursors) but not in the ﬁeld itself.
Similarly, Sall1 expression was maintained in the second heart ﬁeld (outﬂow tract/right ventricle precursors)
but not in cardiac cells. In vitro, high levels of Sall1 at mesodermal stages enhanced cardiomyogenesis, whereas
its continued expression suppressed cardiac differentiation. Our study demonstrates that Sall1 marks CPCs in an
undifferentiated state and regulates cardiac differentiation. These ﬁndings provide fundamental insights into CPC
maintenance, which can be instrumental for CPC-based regenerative medicine.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Cardiac progenitor cells (CPCs), identiﬁed from embryos or pluripo-
tent stem cell (PSC) culture, hold tremendous regenerative potential
with the unique capability to expand and differentiate into cardiac cells
[1]. Cardiogenesis initiate as the basic-helix-loop-helix factor Mesp1 is
expressed in precardiac mesoderm. Mesp1+ cells migrate and form the
cardiac crescent (referred to as the ﬁrst heart ﬁeld (FHF)), which largely
contribute to the left ventricle (LV). A subset of Mesp1+ cells remain un-
differentiated in the second heart ﬁeld (SHF), located dorsal to the FHF,
and give rise to the outﬂow tract (OFT), right ventricle (RV), and part of
atria [2]. Early CPCs can be identiﬁed by transient expression of the chro-
matin factor Smarcd3, prior to expression of known CPC markers [3, 4],lar Regeneration, Institute of
yo, 1-1-1, Yayoi, Bunkyo, Tokyo
hi@iam.u-tokyo.ac.jp
. This is an open access article underincluding Islet1 (Isl1), fetal liver kinase 1 (Flk1), and Nkx2.5 [1]. While
Isl1 is transiently expressed in the SHF, Smarcd3 and Nkx2-5 are continu-
ally expressed in cardiomyocytes [5, 6]. Although, CPCs can be identiﬁed
by their stage-speciﬁc expression of various cell markers, no gene has
been identiﬁed to mark undifferentiated pools of CPCs giving rise to
four chambers throughout development. In the present study,wedemon-
strate that Sall1, a zinc-ﬁnger transcription factor, is transiently expressed
andmaintained in undifferentiated CPCs throughout early heart develop-
ment in vivo. Sall1 has a biphasic role: early overexpression of Sall1 en-
hanced, but its late overexpression suppressed cardiomyogenesis in
pluripotent stem cell (PSC) culture.
2. Materials and methods
2.1. Mice and lineage tracing
Sall1GFP, Sall1CreERT2, ROSAYFPmouse lineswere generated as described
[7, 8]. Experiments were conducted according to a protocol approved by
the International Animal Care andUse Committee of IMCB, the Universitythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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stage, pregnant mice were fed 150 μl/30 g of Tamoxifen (10 mg/ml:
sigma) by injection into the abdominal cavity at desired time points.
2.2. PSC generation, maintenance, and differentiation
Sall1GFP/+ ESCs were derived from Sall1GFP/+ mice [9]. ESCs were
maintained in Knockout DMEM supplemented with 15% KSR (Gibco),
Penicillin-Streptomycin (Nacalai tesque), MEM-NEAA, GlutaMAX, Sodi-
um Pylvate, 2-mercaptoethanol (Gibco), LIF (WAKO) onMEF. To differ-
entiate Sall1-GFP ESCs, embryoid bodies (EB) were generated with
DMEM (KOHJIN BIO) containing 20% FBS, 2.4 mM L-glutamine, MEM
NEAA, 2-mercaptoethanol (Gibco), LIF (WAKO). After 2 days, EBs were
cultured in DMEM (KOHJIN BIO) containing 20% FBS, 2.4 mM L-gluta-
mine, 2-mercaptoethanol (Gibco). The medium was changed every
two days. To generate time dependent Sall1 overexpressing cells, A
DOX inducible SALL1 expressing piggybac vector and a PB-EF1a-
mSALL1-IRES-mcherry vector were co-electroporated with the
piggybac transposase vector PBASE2 into 201B7 cells [10] with
NEPA21 (NEPA GENE) [11]. DOX-SALL1 hiPSCs were maintained and
differentiated as described [12].
2.3. Immunohistochemistry and ﬂow cytometry
Antibodies used: mouse a-Sall1 (1:100, PPMX), rabbit a-Isl1 (1:200,
Abcam),mouse a-Isl1 (1:100, hybridomabank), goat a-Nkx2-5 (1:2000,
Santa Cruz Biotechnology), rabbit a-GFP (1:400, MBL), chick a-GFP
(1:400, Life technologies), rat a-CD31 (1:100, BD biosciences), mouse
a-cTnT (1:10,000, Thermo Fisherscientiﬁc), rabbit a-HCN4 (1:2000,
alomone lab). Alexa Fluor secondary antibodies (Life technologies)
were used for secondary detection and images were acquired with a
KEYENCE BZ-9000 Fluorescence Microscope. For ﬂow cytometry, ESCs/
iPSCs were dissociated using 0.1% Trypsin or Accumax (Funakoshi).
Cells were re-suspended in 0.1%FBS/D-PBS(−) without Ca2+ and
Mg2+ and sorted using a FACSAriaIII (BD Biosciences). Cells were incu-
bated with primary antibodies followed by secondary antibodies conju-
gated with Alexa Fluor 647 (Invitrogen).
2.4. Chromatin immunoprecipitation (ChIP)
ChIPwas done using antibodies against a-trimethylated H3K27 (Cell
Signaling), and a-acetylated H3K27 (Abcam) as described [13].
Immunoprecipitated DNA was ampliﬁed using the primer pairs:
Isl1 3.2F 5-CCAATCTAGTGAGCAGGCAAA-3,
Isl1 3.2R 5-TCAAGTTTCAGGAGGAACCAAG-3,
Isl1 3.1F 5-TCAGTGGGCACTGGCTCAA-3,
Isl1 3.1R 5-GCTAGCAGTGGATAAAGGGCATC-3,
Flk1 F 5-CAGGATAGGGAAGCCTTGGA-3,
Flk1 F 5-CCACCATGCCCAGCTTACTT-3.
3. Results
3.1. Sall1 is expressed in early CPCs during development
To examine Sall1 expression during heart development, we used
Sall1GFP mice [9] and compared GFP expression with Mesp1-lineage
cells by generating Sall1GFP; Mesp1cre; ROSARFP mice. Sall1 expression
was initially observed at embryonic day 7 (E7.0) in the nascent me-
soderm, prior to the emergence of embryonic Mesp1-lineage cells
(Fig. 1A). Unlike Mesp1-lineage cells, Sall1 was not expressed in
the extraembryonic tissue (Fig. 1A). At the crescent stage (E7.5),
the Sall1 expression domain was adjacent to, but non-overlapping
with, the domain of Nkx2-5 expression that represents the FHF
(Fig. 1B). Expression of Sall1 and Nkx2-5 continued in complementa-
ry patterns throughout heart development (Fig. 1B, C). In contrast,Sall1 was expressed in the SHF where Isl1 is expressed (Fig. 1D).
Thus, Sall1 is expressed in the mesoderm at pre-heart ﬁeld stages
and in SHF cells from heart ﬁeld stages, but is not expressed in FHF
cells.
3.2. Sall1+ cells give rise to distinct anatomical structures of the heart
in vivo
To determine the fate of Sall1+ CPCs during heart development, we
performed lineage-tracing experiments with Sall1creERT2; R26RYFP line-
age reporter mice [7, 8] (Fig. 1E). Cre activity was induced at different
stages (E5.5–E9.5) by tamoxifen, and hearts were analyzed for YFP
expression at E10.5 (Fig. 1F). Cre activation prior to gastrulation (E5.5)
resulted in widespread distribution of YFP positive cells in the heart.
However, when Cre activity was induced at crescent stages (E7.5), YFP
positive cells were mostly conﬁned to the OFT and RV. Later stages of
Cre activation (E8.5 and E9.5) resulted in further restriction of YFP
positive cells to OFT/RV cells (Fig. 1F). Next, we induced Cre activa-
tion at E7.0 and E9.0, collected hearts at E14.5, and analyzed YFP
positive cells. Cre activation at the pre-crescent stage (E7.0) resulted
in abundant appearance of YFP cells in the entire heart (Fig. 1G). His-
tological analysis of the hearts revealed YFP positive progeny in atri-
al and ventricular cardiomyocytes (Figs. 1H1 and 2), epicardial cells
(Fig. 1H2; arrowheads), endothelial cells (Fig. 1H3), pacemaker cells
in sinoatrial node (Fig. 1H4). Cre induction at E9.0 resulted in a pro-
nounced reduction of YFP cells within the left ventricle (Fig. 1G),
with YFP cells primarily restricted to the RV. These results suggest
that Sall1 is expressed in precursors of FHF and SHF cells during gas-
trulation, and remains expressed in the SHF before giving rise to the
OFT/RV.
3.3. Sall1 positively regulates CPC genes
To examinewhether Sall1 affects cardiogenesis in vitro, we differenti-
ated Sall1GFP ESCs into precardiac mesodermal cells and isolated GFP+/
GFP− cells (Fig. S1A, B histogram). The GFP+ cells showed enrichment
for Flk1 and Pdgfra along withMesp1 compared to GFP− cells (Fig. S1D),
indicating that the Sall1+ cells contain early precardiac mesodermal
cells. Isl1 was also enriched along with Foxa2/Foxc2 and Six2, which
are involved in regulating progenitor renewal, suggesting the ESC-
derived Sall1+ cells contain both early and SHF progenitors. The
GFP+ cells were efﬁciently differentiated into cardiomyocytes
(Fig. S1B, C) with increased levels of contractile genes (Fig. S1E).
Isl1 levels were maintained even after 8 days of culture, but this is
likely due to an ESC culture effect [14]. Through bioinformatics anal-
yses, we identiﬁed putative Sall1-binding sites near loci of Isl1 and
Flk1 (Fig. S1F). Our ChIP assay showed that the sites were poorly as-
sociated with H3K27me3 or showed no change in GFP+ cells as com-
pared to GFP− cells (Fig. S1F). In contrast, the sites were highly
associated with H3K27ac in GFP+ cells, suggesting they are tran-
scriptionally active in Sall1+ CPCs (Fig. S1F).
3.4. Mesodermal SALL1 expression promotes cardiac fate but its prolonged
expression suppresses cardiac differentiation
To temporally control Sall1 expression, we generated human PSCs
that stably express a reverse tetracycline-controlled transactivator
(rtTA) and a doxycycline (DOX)-inducible expression cassette containing
Sall1 andmCherry (Sall1-TGhiPSCs) [11] (Fig. 2A). Expression of exoge-
nous Sall1 and mCherry was observed within 12 h (maintaining its
expression for 2 days) following DOX treatment (Fig. 2B, C). Cardiac
differentiation was performed with a step-wise developmental pro-
gression from a primitive streak-like population (days 1–3) to early
precardiac mesoderm (days 3–4), CPC speciﬁcation (days 4–7), and
cardiomyocyte formation (after day 7) (Fig. S2A). Molecular proﬁl-
ing showed that SALL1 is initially upregulated during mesodermal
Fig. 1. Sall1 is expressed in nascentmesoderm and SHF giving rise to four chamber cells. (A) Sall1 expression was observed in nascentmesoderm at E7.0 whenMesp1 lineage cells appear
in extraembryonic tissue. (B) Sall1 is not expressed in the FHF. Immunostaining shows that Sall1 expression (green) does not overlap with the FHF marker Nkx2-5 (red) at E7.5–8.5.
(C, D) Sall1 overlaps with the SHF marker Isl1 (D, red) and remains in the SHF, but not expressed in the heart (C). (E) Schematic diagram of Sall1 lineage analysis. (F, G) Analysis of
Sall1-lineage cells with YFP signal on E10.5 (F) or E14.5 (G) heart. Sall1+ cells from the early stages (E5.5/E7.0) contribute to the whole heart, whereas Sall1+ cells from the later
stage (E7.5–9.5) contribute to the OFT and RV. Isl1 lineage was also traced for comparison (G). (H) Section of Sall1 lineage-traced heart showing its contribution to atria/ventricular
cardiomyocytes (1), epicardial cells (2, arrows), endothelial cells merged with CD31 (3, red), and SAN cells with HCN4+ (4, red) analyzed at E14.5 heart. Scale bars: 20 μm (B, C),
50 μm (A, D, F), 100 μm (H), 200 μm (G). A, anterior; P, posterior; EE, extraembryonic; E, embryonic; CC, cardiac crescent; HT, heart tube; OFT, outﬂow tract; RV, right ventricle; LV, left
ventricle, TM, tamoxifen.
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found that DOX treatment during CPC stages markedly increased ex-
pression of cardiac genes (Fig. 2D). However, continued DOX treat-
ment at later stages strongly prevented cardiac gene expression
(Fig. 2D). Consistently, the number of cardiomyocyte was markedly
increased with early DOX treatment and decreased with late DOX
treatment (Fig. 2E).4. Conclusion
The present study shows that Sall1 is a previously unrecognized CPC
gene expressed speciﬁcally in undifferentiated cells during CPC devel-
opment. The absence of Sall1 expression in the FHF suggests that Sall1
is amaker of undifferentiated CPCs as, unlike SHF cells, FHF cells express
sarcomere genes [15]. Sall1 expression was also maintained in the SHF
Fig. 2.Mesodermal SALL1 expression promotes cardiac fate but its continued expression in CPCs suppresses cardiac differentiation. (A)DOX-inducible Sall1 construct and strategy for temporal
SALL1 overexpression in human PSCs (Sall1-TGhiPSc). (B, C) mCherry (B) or exogenous Sall1 (C) expression with/without DOX (after 2 days). This level of SALL1 expression is about six-fold
higher than endogenous levels (Fig. S2B), which may be appropriate for the assay. Scale bars: 200 μm. (D) Relative expression of cardiac transcription factors and myocardial genes after
temporal DOX treatment shown in (A). (E) Flow cytometry analysis showing percentages of cTNT/TNI/KDR positive cells after temporal DOX treatment shown in (A).
161Y. Morita et al. / Journal of Molecular and Cellular Cardiology 92 (2016) 158–162from mesodermal stages. These ﬁndings suggest that Sall1+ cells rep-
resent an undifferentiated population of CPCs. In agreement with this,
a temporal increase in Sall1 levels at early stages enhanced the cardio-
genic potential, whereas its prolonged expression suppressed cardiac
differentiation. Genome-wide ChIP analysis may allow us to identify a
set of CPC genes crucial for maintaining CPCs in an undifferentiated
state.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.yjmcc.2016.02.008.
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